2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. Aurora Kinase

Aurora Kinase

Aurora Kinase

Related Products

PDF 0.27 MB

The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C). Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function.

Aurora-A, Aurora-B, and Aurora-C share a highly conserved kinase domain but have quite different subcellular localizations and functions during mitosis. Aurora-A mostly controls centrosome maturation and bipolar spindle assembly, while Aurora-B and Aurora-C are required for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis. In human tumors, all Aurora kinase members play oncogenic roles related to their mitotic activity and promote cancer cell survival and proliferation. Inhibitors targeting Aurora kinases have attracted attention in cancer research.

Aurora Kinase Isoform Specific Products:

Aurora Kinase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10339R
    KW-2449 (Standard)
    		Inhibitor
    KW-2449 (Standard) is the analytical standard of KW-2449 (HY-10339). This product is intended for research and analytical applications. KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABLT315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.
    KW-2449 (Standard)
  • HY-W395613
    TY-011
    		Inhibitor
    TY-011 is an Aurora A/B kinase inhibitor. TY-011 induces abnormal microtubule-kinetochore attachment, leading to DNA damage and apoptosis (Apoptosis) in human gastric cancer cells, and ultimately inhibits cancer cell proliferation, with an IC50 value ranging from 0.11 to 4.49 μM in human gastric cancer cell lines. TY-011 has potential applications in gastric cancer research.
    TY-011
  • HY-10161R
    Tozasertib (Standard)
    		Inhibitor
    Tozasertib (Standard) is the analytical standard of Tozasertib (HY-10161). This product is intended for research and analytical applications. Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with Kis of 0.6, 18, 4.6 nM, respectively.
    Tozasertib (Standard)
  • HY-123279
    OM137
    		Inhibitor
    OM137 is an aurora kinase inhibitor, with an IC50 of 21.7 μM (Aurora A kinase) and 2.4 μM (Aurora B kinase). OM137 also inhibits Cdk1/cyclinB and Cdk5/p25 with an approximate IC50 of 20 μM. OM137 reduces spindle checkpoint-signaling proteins (Mad2 and BubR1) at the kinetochores of chromosomes.
    OM137
  • HY-10057
    AT9283 hydrochloride
    		Inhibitor
    AT9283 hydrochloride is a multi-targeted kinase inhibitor with anti-tumor activity. AT9283 hydrochloride has been found to effectively inhibit Aurora A and Aurora B kinases, thereby affecting cell proliferation and survival. AT9283 hydrochloride can also inhibit several other kinases, including JAK2 and Abl (T315I).
    AT9283 hydrochloride
  • HY-123697
    VE-465
    		Inhibitor
    VE-465 is an Aurora kinase inhibitor. VE-465 induces cancer cell apoptosis. VE-465 has anticancer effects in multiple tumor models.
    VE-465
  • HY-10558R
    CYC-116 (Standard)
    		Inhibitor
    CYC-116 (Standard) is the analytical standard of CYC-116 (HY-10558). This product is intended for research and analytical applications. CYC-116 is a potent aurora A and aurora B inhibitor with Kis of 8 and 9 nM, respectively.
    CYC-116 (Standard)
  • HY-107419R
    NU6140 (Standard)
    		Inhibitor
    NU6140 (Standard) is the analytical standard of NU6140 (HY-107419). This product is intended for research and analytical applications. NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs. NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively. Enhances the apoptotic effect, with anti-cancer activity.
    NU6140 (Standard)
  • HY-10127R
    Barasertib (Standard)
    		Inhibitor
    Barasertib (Standard) is the analytical standard of Barasertib. This product is intended for research and analytical applications. Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells.
    Barasertib (Standard)
  • HY-121998
    Binucleine 2
    		Inhibitor
    Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki=0.36 μM), a kinase involved in cell division. It is specific for Drosophila Aurora B kinase, inhibiting it in a dose-dependent manner, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 μM. Binucleine 2 induces mitotic and cytokinesis defects in Drosophila Kc167 cells. It prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 μM but does not affect ring ingression, suggesting that Aurora B kinase activity is not required for that step.
    Binucleine 2
  • HY-169735
    Aurora A inhibitor 4
    		Inhibitor
    Aurora A inhibitor 4 (compound C9) is a potent inhibitor of Aurora A, with the GI50 of 4.26 and 7.08 μM in DU 145 cells and HT-29 cells, respectively.
    Aurora A inhibitor 4
  • HY-10128R
    ZM-447439 (Standard)
    		Inhibitor
    ZM-447439 (Standard) is the analytical standard of ZM-447439 (HY-10128). This product is intended for research and analytical applications. ZM-447439 is an aurora kinase inhibitor with IC50s of 110 and 130 nM for aurora A and B, respectively.
    ZM-447439 (Standard)
  • HY-10483R
    SCH-1473759 hydrochloride (Standard)
    		Inhibitor
    SCH-1473759 hydrochloride (Standard) is the analytical standard of SCH-1473759 hydrochloride (HY-10483). This product is intended for research and analytical applications. SCH-1473759 hydrochloride is an aurora inhibitor with IC50s of 4 and 13 nM for aurora A and B, respectively.
    SCH-1473759 hydrochloride (Standard)
  • HY-10126R
    Barasertib-HQPA (Standard)
    		Inhibitor
    Barasertib-HQPA (Standard) is the analytical standard of Barasertib-HQPA (HY-10126). This product is intended for research and analytical applications. Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.
    Barasertib-HQPA (Standard)
  • HY-10971R
    Alisertib (Standard)
    		Inhibitor
    Alisertib (Standard) is the analytical standard of Alisertib. This product is intended for research and analytical applications. Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity.
    Alisertib (Standard)
  • HY-50514R
    AT9283 (Standard)
    		Inhibitor
    AT9283 (Standard) is the analytical standard of AT9283. This product is intended for research and analytical applications. AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.
    AT9283 (Standard)
  • HY-W100186
    Win 47338
    		Control
    Win 47338 (compound 14) is a control compound of inhibitors of the mitotic kinase monopolar spindle MPS1 and Aurora kinases (AurA/AurB) (Ki>100 μM).
    Win 47338
  • HY-U00304
    Aurora B inhibitor 1
    		Inhibitor
    Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
    Aurora B inhibitor 1
Cat. No. Product Name / Synonyms Application Reactivity
Aurora Kinase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.